BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29358174)

  • 1. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
    Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
    Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling between immunological synapse formation and functional outcome in human gamma delta T lymphocytes.
    Favier B; Espinosa E; Tabiasco J; Dos Santos C; Bonneville M; Valitutti S; Fournié JJ
    J Immunol; 2003 Nov; 171(10):5027-33. PubMed ID: 14607899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
    Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
    J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
    Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
    Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
    Lafont V; Liautard J; Liautard JP; Favero J
    J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.
    Nedellec S; Sabourin C; Bonneville M; Scotet E
    J Immunol; 2010 Jul; 185(1):55-63. PubMed ID: 20511557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown.
    Trichet V; Benezech C; Dousset C; Gesnel MC; Bonneville M; Breathnach R
    J Immunol; 2006 Nov; 177(9):6129-36. PubMed ID: 17056540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
    Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
    Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer.
    Laplagne C; Meddour S; Figarol S; Michelas M; Calvayrac O; Favre G; Laurent C; Fournié JJ; Cabantous S; Poupot M
    Front Immunol; 2020; 11():1396. PubMed ID: 32733462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.
    Daguzan C; Moulin M; Kulyk-Barbier H; Davrinche C; Peyrottes S; Champagne E
    J Immunol; 2016 Mar; 196(5):2219-29. PubMed ID: 26819204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
    Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
    Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpaca (
    Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.
    Wiemer DF; Wiemer AJ
    Biochem Pharmacol; 2014 Jun; 89(3):301-12. PubMed ID: 24680696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
    Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
    Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.